Funny Business: Pfizer CEO Caught In Shady Stock Sale After COIVD Vaccine Volunteers Admit Some Shocking Results
Yesterday we reported that one of the largest legal groups in the country, the New York Bar gave the legal two thumbs up for the state to allow mandatory COVID-19 vaccines, regardless of religious preference.
What could possibly go wrong?
As it turns out volunteers who offered to receive the vaccine reported that the side effects from the vaccine were worse than what they would have experienced if they got the virus.
For a lot of people under the age of 55 who contracted the coronavirus they kicked it in a day, some (like myself) had the migraine, sweats, and a fever for one night, others merely had a cough and sniffles.
However, some of the volunteers who received the coronavirus vaccine reported symptoms worse than the virus.
Trial volunteer Glenn Deshields, 44, from Austin, Texas said he felt like he had “a severe hangover.”
Carrie, from Missouri, 45, said she got a headache, fever, and body aches after receiving the vaccine.
The trial is double-blinded, so the participants don’t know if they received the vaccine or a placebo. However, Deshields got an antibody test and it came back positive, confirming his thoughts he received the actual vaccine.
The vaccine is expected to be launched first in the UK who is expected to get approval very soon. The British government is looking to vaccinate the elderly and health care staff first before making it widely available.
As news is coming out about the vaccine the CEO of Pfizer decided to make sure he gets even richer before the vaccine is available.
Stocks shares for Pfizer soared after the announcement was made the vaccine for the coronavirus has been developed and is successful. No doubt knowing the data that vaccine side effects could be worse than if one got the virus and that would affect stock prices, CEO Albert Bourla decided to cash out now.
CNBC reports:
Shares of Pfizer jumped by almost 15% on Monday after the company and its partner BioNTech said its vaccine was more than 90% effective in preventing Covid-19 among those in the trial without evidence of prior infection.
Bourla sold 132,508 shares at an average price of $41.94 per share, or nearly $5.6 million, according to a securities filing.
Not exactly heartwarming.
I’m not trying to minimize the virus, it has taken a lot of lives. Many of you lost family members or know of people (including myself) who lost family members to the virus.
It would be really nice if we had six months of data before we shove a needle of a vaccine into the arms of hundreds of millions of people.
It seems very shady that the CEO who developed the vaccine decided to cash out before the vaccination is widely distributed (one would think stock prices would bust through the ceiling). However, it makes sense if the side effects could be worse than the actual virus for healthy adults.
